Moderna (MRNA) stock is in focus as its updated mNEXSPIKE COVID vaccine boosts antibodies 15-fold on average against the new ...

Moderna Inc. (NASDAQ:MRNA) on Tuesday released preliminary immunogenicity data for the 2025-2026 formula of mNEXSPIKE ...

Discover why Moderna (MRNA) and MRNY ETF present high risks and limited upside for investors. Learn why avoiding both is the ...

Preliminary analysis showed the 2025-2026 formula of Spikevax generated greater than an 8-fold increase in ...

Preliminary analysis showed the 2025-2026 formula of mNEXSPIKE generated greater than a 16-fold increase in LP.8.1-neutralizing antibodies across age groups Both of Moderna’s COVID-19 vaccines for the ...

Moderna said on Tuesday its updated COVID-19 vaccine formulation elicited a strong immune response in all adults aged 65 and older, as well as in individuals aged 12 to 64 with at least one underlying ...

Moderna said on Tuesday its updated COVID-19 vaccine formulation elicited a strong immune response in all adults aged 65 and ...

Moderna shares rose by over 4% on a mixed Tuesday for US equities ahead of the US Federal Reserve's rate cut decision today.

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 6.1% in the afternoon session after the company announced it ...

Moderna Inc. (NASDAQ:MRNA) on Tuesday released preliminary immunogenicity data for the 2025-2026 formula of Spikevax, which targets the LP.8.1 variant of SARS-CoV-2 to help prevent COVID-19. The ...

Moderna said on Tuesday its updated COVID-19 vaccine elicited a strong immune response in all adults age 65 and older, as ...

Moderna (MRNA) announced “positive” preliminary immunogenicity data for the 2025-2026 formula of Spikevax, which targets the LP.8.1 variant of ...